SLC7A8: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: SLC7A8

NCBI ID: G23428

Other Name(s): integral membrane protein E16H | Large neutral amino acids transporter small subunit 2 (isoform a) | SLC7A8 variant 3 | Solute carrier family 7 member 8, transcript variant 1 | Integral membrane protein E16H | Solute carrier family 7 member 8, transcript variant 4 | Solute carrier family 7 member 8 | L-type amino acid transporter 2 | LAT2 | solute carrier family 7 member 8 | LAT2_HUMAN | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 | SLC7A8 variant 1 | Solute carrier family 7 (amino acid transporter, L-type), member 8 | Large neutral amino acids transporter small subunit 2 | SLC7A8 variant 4 | hLAT2 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 | Solute carrier family 7 (amino acid transporter light chain, L system), member 8 | HLAT2 | solute carrier family 7 (amino acid transporter light chain, L system), member 8 | LPI-PC1 | Large neutral amino acids transporter small subunit 2 (isoform c) | Solute carrier family 7 member 8, transcript variant 3 | Large neutral amino acids transporter small subunit 2 (isoform d) | solute carrier family 7 (amino acid transporter, L-type), member 8

SLC7A8: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of chronic pain can lead to significant disability and decreased quality of life. Additionally, the rising burden of healthcare costs associated with managing chronic pain further highlights the need for effective new treatments. Sodium-glucose cotransporter 7A (SLC7A8), a member of the GLUT family, has been identified as a potential drug target and biomarker for chronic pain.

SLC7A8 function and localization

SLC7A8 is a transmembrane protein that plays a critical role in the regulation of intracellular glucose levels. It is expressed in various tissues and cell types, including endothelial cells, pericytes, and epithelial cells. SLC7A8 functions as an integral membrane protein, participating in the regulation of Na+ and K+ transport across the end membrane. It also interacts with various intracellular signaling pathways, including the TGF-β pathway.

SLC7A8 is a key regulator of the TGF-β pathway

The TGF-β pathway is a well-established signaling pathway that plays a crucial role in the development and maintenance of tissues, including muscles, bones, and tissues. SLC7A8 is a critical regulator of TGF-β pathway, as it has been shown to interact with multiple TGF-β signaling proteins, including SMAD4 and TGF-β1. SLC7A8 has been shown to regulate the activity of SMAD4, a transcription factor that plays a critical role in the regulation of gene expression. Additionally, SLC7A8 has been shown to modulate the activity of TGF-β1, which is involved in the regulation of cell growth, differentiation, and survival.

SLC7A8 as a drug target

SLC7A8 has been identified as a potential drug target for chronic pain due to its involvement in the regulation of pain signaling pathways. Several studies have shown that SLC7A8 is involved in the regulation of pain perception and neuroinflammation. For instance, SLC7A8 has been shown to regulate the activity of N-methyl-D-aspartate (NMDA) receptor, which is involved in pain perception. Additionally, SLC7A8 has been shown to modulate the activity of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which are involved in the regulation of pain and inflammation.

SLC7A8 as a biomarker

SLC7A8 has also been identified as a potential biomarker for chronic pain due to its involvement in the regulation of pain signaling pathways. Several studies have shown that SLC7A8 is involved in the regulation of pain perception and neuroinflammation, and its activity can be used as a biomarker for the assessment of pain intensity and persistence. For instance, SLC7A8 has been shown to be involved in the regulation of pain-related neuro chemosites, including nitric oxide (NO) and corticosteroids. Additionally, SLC7A8 has been shown to play a critical role in the regulation of pain-related gene expression, including the expression of genes involved in pain perception and neuroinflammation.

Conclusion

SLC7A8 is a transmembrane protein that plays a critical role in the regulation of intracellular glucose levels and the TGF-β pathway. Its involvement in the regulation of pain signaling pathways makes it a potential drug target and biomarker for chronic pain. Further research is needed to fully understand the role of SLC7A8 in pain regulation and to develop effective new treatments for chronic pain.

Protein Name: Solute Carrier Family 7 Member 8

Functions: Sodium-independent, high-affinity transport of small and large neutral amino acids such as alanine, serine, threonine, cysteine, phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Acts as an amino acid exchanger. Has higher affinity for L-phenylalanine than LAT1 but lower affinity for glutamine and serine. L-alanine is transported at physiological concentrations. Plays a role in basolateral (re)absorption of neutral amino acids. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. Plays an essential role in the reabsorption of neutral amino acids from the epithelial cells to the bloodstream in the kidney

More Common Targets